Louisiana Pharmacy Banned from Handling Controlled Drugs Forever
Published Date: 1/23/2025
Notice
Summary
Neumann's Pharmacy in Louisiana lost its DEA registration because it didn’t meet important pharmacy rules that keep the public safe. After a full hearing and review, the government decided to revoke their license, meaning they can’t legally handle controlled medicines anymore. This change takes effect soon and could impact the pharmacy’s business and customers relying on their services.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Revokes Pharmacy's Controlled‑Substance License
If you own or operate Neumann's Pharmacy, LLC (DEA Certificate of Registration FN4373293), the DEA revoked the pharmacy's registration after a hearing and adopted the Administrative Law Judge's June 18, 2024 recommendation. The revocation means the pharmacy can no longer legally handle or dispense controlled substances; the action was published in the Federal Register on January 23, 2025.
Patients Lose Access To Controlled Medications
If you are a customer of Neumann's Pharmacy who relies on controlled medications, you will no longer be able to obtain controlled substances from that pharmacy after the DEA revoked its registration (FN4373293). The revocation followed an Order to Show Cause issued September 12, 2023 and a recommended decision on June 18, 2024, with the decision published January 23, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-01533 — Notice of December 2025 Federal Accounting Standards Advisory Board Meeting
Heads up! The Federal Accounting Standards Advisory Board (FASAB) has moved its December 2025 meeting to a new date. This matters to government accountants and anyone who follows federal money rules because it could speed up or change how financial standards get updated. Keep an eye out for the new schedule to stay in the loop and avoid missing important updates!
Next: 2025-01537 — Xubex Community Pharmacy; Decision and Order
Xubex Community Pharmacy in Florida lost its DEA registration because it was seen as a danger to public health. The pharmacy didn’t ask for a hearing to defend itself, so the suspension became final. This means Xubex can’t legally handle controlled substances anymore, effective immediately, impacting their business and customers.